Bryant Lab

Bryant Lab

Dr. Bryant and another scientist conducting an experiment

Personal Statement

I am a Physician-Scientist, and an Early Stage Investigator, devoted to establishing a career as an independent researcher in the area of pulmonary hypertension associated with chronic lung disease (World Health Organization Group III Pulmonary Hypertension). 

My clinical focus is on evaluating patients with pulmonary hypertension secondary to ILD or COPD. Additionally, I preserve 75% of my effort within the laboratory, afforded by my NIH K08 award, and other career development awards.  Broadly, our group pulls from the vast knowledge base offered within our research environment, drawing on collaborators in the fields of immunology (specifically, myeloid-derived suppressor cells ), vascular disease (systemic and pulmonary hypertension), pulmonary fibrosis, and circadian processes. 

Research Support

Ongoing

  • University of Florida Clinical and Translational Science Institute,“Vascular Hypoxic Signaling Regulation of Pulmonary Hypertension,” Pearson (P1), 01/16/2016-12/01/2017.
  • Gilead Sciences Research Scholars Program in Pulmonary Hypertension“Role of myeloid-derived suppressor cell trafficking in development of pulmonary hypertension,” Bryant (PI), 01/17/2017-12/31/2018.
  • American Lung Association — Biomedical Research Grant, “Role of CXCR2-mediated cell trafficking in pulmonary hypertension,” Bryant (PI), 07/01/2017-06/30/2018.
  • Institutional Start-Up Funds. University of Florida College of Medicine, Gatorade Fund, Bryant (PI), 07/01/2014- 06/30/2018.
  • Margaret Q. Landenberger Research Program, Bryant (PI) 01/31/2017-01/31/2019.

Completed

  • University of Florida Institute on Aging, UF OAIC Pilot Award, Leeuwenburgh (PI), 08/01/2015-03/31/2016.
  • NIH/NHLBI, “Clinical and Translational Research Training Program in Pulmonary Medicine,” Bernard (PI), 041/01/2007-06/30/2014.
  • American Thoracic Society $50,000, “Hypoxia Inducible Factor Regulation of Secondary Pulmonary Hypertension,” Bryant (PI), 01/15/13-01/14/14.

Publication Highlights

  • Bryant AJ, Shenoy V, Fu Chunhua, Marek G, Lorentsen KJ, Herzog EL, Brantly ML, Avram D, Scott EW. Myeloid-derived suppressor cells are necessary for the development of pulmonary hypertension. Am J Respir Cell Mol Biol. 2017 (In press).
  • Bryant AJ, Carrick RC, McConaha ME, Jones BR, Shay SD, Moore CS, Blackwell TR, Gladson S, Penner NL, Burman A, Tanjore H, Hemnes AR, Karwandyar AK, Polosukhin VV, Talati MA, Dong H-J, Gleaves LA, Carrier EJ, Gaskill C, Scott EW, Majka SM, Fessel JP, Haase VH, West JD, Blackwell TS, Lawson WE. Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 Feb 1;310(3):L249-62.
  • Bryant AJ and Scott EW. “A small leak will sink a great ship”: hypoxia-inducible factor and group III pulmonary hypertension. Receptors Clin Investig. 2016;3(1). pii: e1213. Epub 2016 Mar 14.
  • Bryant AJ, Robinson LJ, Moore CS, Blackwell T, Gladson S, Penner NL, Burman A, McClellan LJ, Polosukhin V, Tanjore H, McConaha ME, Gleaves LA, Talati M, Hemnes AR, Fessel JP, Blackwell TS, Lawson WE, and West J. Expression of mutant BMPR2 worsens pulmonary hypertension secondary to pulmonary fibrosis. Pulm Circ. 2015 Dec;5(4):681-90.
  • PubMed: https://www.ncbi.nlm.nih.gov/sites/myncbi/1nOMrXCyL6CkP/bibliography/48049119/public/?sort=date&direction=ascending